Benefits
Increased energy expenditure / thermogenesis
In the 70-person AfperFIT trial, measured energy expenditure rose by about 209 kcal per day over 12 weeks while the placebo group was essentially unchanged (p<0.01). Smaller non-branded studies link grains of paradise to brown fat activation, but one of them raised energy expenditure only in people who already had active brown fat.
Visceral fat reduction
In the AfperFIT trial, visceral fat area fell by about 17 square centimeters over 12 weeks while it rose in the placebo group (p<0.001), and the AfperFIT group lost about 4 kg of body weight against 0.8 kg on placebo. This is one manufacturer-run trial in 70 people and has not been independently repeated.
Caffeine-free metabolic support
It contains no caffeine, so it suits people who want to avoid stimulants. Two caveats: the TRP channel step comes from animal and cell work and was not measured in any human trial, and the proposed route still runs through sympathetic nervous system signaling rather than bypassing it.
Mechanism of action
Brown adipose tissue activation
6-Paradol and related pungent compounds activate TRPV1 channels, stimulating sympathetic signaling that switches on calorie-burning brown fat. This chain was worked out in animal and cell studies; the human trials measured energy expenditure and brown fat activity, not the channels themselves.
Sympathetic thermogenesis
The resulting rise in energy expenditure and fat oxidation underlies the visceral-fat findings.
Clinical trials
Randomized, double-blind, placebo-controlled, 250 mg twice daily for 12 weeks. Published in Drug Design, Development and Therapy in 2022 (PMID 36329722) and registered as CTRI/2019/03/017956. Funded and run by Vidya Herbs is not claimed here: the study was conducted by Vidya Herbs, with two of the four authors employed by the company.
Overweight adults
70 overweight men and women, BMI 25 to 30, aged 20 to 50. Energy expenditure rose about 209 kcal per day, visceral fat area fell about 17 square centimeters, and body weight fell about 4 kg, each significantly better than placebo, with energy expenditure by indirect calorimetry, body composition by DEXA and fat distribution by CT. Safety labs stayed in normal range and no adverse effects were reported. Treat it as single-trial, manufacturer-run evidence until an independent group repeats it.
Three small single-blind crossover studies from the same Japanese group: 40 mg as a single dose in 19 men (2013), 30 mg daily for 4 weeks in 19 women (2014), and 40 mg daily for 5 weeks in 9 men selected for low brown fat activity (2021). None of them tested AfperFIT.
Healthy adults
Healthy young volunteers, 9 to 19 per study. A single 40 mg dose raised energy expenditure only in people who already had active brown fat, not in those without it. Four weeks of 30 mg daily lowered visceral fat area, and 5 weeks of 40 mg daily raised cold-induced thermogenesis and slightly lowered body fat percentage in the 9 selected men, though resting energy expenditure did not change in that study.